ProfoundBio US Co.
🇺🇸United States
PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)
Phase 1
Recruiting
- Conditions
- Renal Cell CarcinomaNasopharyngeal CarcinomaNon Hodgkin Lymphoma
- Interventions
- Drug: PRO1160
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- ProfoundBio US Co.
- Target Recruit Count
- 134
- Registration Number
- NCT05721222
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇺🇸City of Hope Comprehensive Cancer Center - Duarte, Duarte, California, United States
🇺🇸Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
PRO1184 for Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Endometrial CancerNon-small Cell Lung CancerHigh Grade Epithelial Ovarian CancerTriple Negative Breast CancerPrimary Peritoneal CarcinomaFallopian Tube CancerEpidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)MesotheliomaBreast AdenocarcinomaPlatinum Sensitive Ovarian Cancer (PSOC)
- Interventions
- Drug: PRO1184Drug: PRO1184 intravenous infusion of PRO1184
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ProfoundBio US Co.
- Target Recruit Count
- 354
- Registration Number
- NCT05579366
- Locations
- 🇨🇳
Hunan Cancer Hospital - Phase 1, Changsha, Hunan, China
🇨🇳Hunan Cancer Hospital - Thoracic Medicine Dept II, Changsha, Hunan, China
🇺🇸University of California Los Angeles Medical Center, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath